Tag: research

Canada’s top research agency sidelines Canadians in a secret hiring practice

An internal audit of the National Research Council (NRC) has uncovered troubling hiring practices that circumvent fairness and transparency, sidelining top Canadian talent.

Over two years, the NRC made at least a dozen “sweetheart appointments” of so-called “top-ranked talent” without posting job vacancies, favouring non-competitive hires in the name of “speed and agility,” as reported by Blacklock’s.

The Audit of Recruitment and Staffing acknowledges the need to attract the “best and brightest” in a competitive global market but warns that bypassing open competition risks undermining trust.

“Circumventing the competitive hiring process should only be considered when candidate availability is extremely limited,” auditors wrote. Yet, the NRC leaned on this tactic 12 times, citing “unique operational requirements” or “urgent needs” without clear justification.

More concerning, the NRC openly prioritized foreign hires, claiming it’s “often not possible to find qualified Canadians” for research roles. In 2021, they even hired consultants to scout international talent, after boasting that Canada had 19 Nobel Laureates, top-tier universities, and $14 billion in annual R&D spending.

Why the rush to look abroad when world-class talent is being cultivated at home?

Keep reading

US Charges Chinese Man Accused of Hacking Into Universities to Steal COVID-19 Research

The Department of Justice (DOJ) announced charges on July 8 against a Chinese national taken into custody in Italy at the behest of Washington, and accused him of hacking into several U.S. universities to steal COVID-19 research at the direction of China’s main intelligence agency.

Xu Zewei, 33, was arrested in Milan, Italy, on July 3 by Italian law enforcement officials and FBI agents as he departed a plane from China. Xu and another Chinese national, Zhang Yu, 44, who remains at large, are charged in a nine-count indictment unsealed in the Southern District of Texas on Tuesday for their alleged involvement in computer intrusions between February 2020 and June 2021.

According to the indictment, Xu was a general manager at a Chinese company called Shanghai Powerock Network, which allegedly conducted hacking operations at the direction of the Shanghai State Security Bureau (SSSB) under China’s Ministry of State Security (MSS).

The DOJ said that Xu’s case exemplifies the Chinese regime’s use of a vast network of private companies and contractors in China to carry out hacking and information theft in a manner that concealed Beijing’s involvement.

“The indictment alleges that Xu was hacking and stealing crucial COVID-19 research at the behest of the Chinese government while that same government was simultaneously withholding information about the virus and its origins,” Nicholas Ganjei, U.S. attorney for the Southern District of Texas, said in a statement.

“The Southern District of Texas has been waiting years to bring Xu to justice and that day is nearly at hand. As this case shows, even if it takes years, we will track hackers down and make them answer for their crimes. The United States does not forget.”

Keep reading

A Rabbi, a Minister, a Monk, and a Priest Took Magic Mushrooms. Here’s What Happened

After scientists asked “psychedelic-naïve” professional religious leaders to take psilocybin, the active ingredient in magic mushrooms, most found the experience “religiously significant, meaningful, and generally beneficial.”

Historically, several world religions incorporate psychedelic compounds in their practices. However, this is the first study to examine what impact these experiences would have on the professional work of leaders from Christianity, Islam, Judaism, and Buddhism, four of the world’s major religions.

Magic Mushrooms and Mystical Experiences

In their published study, the late Roland Griffiths, of Johns Hopkins University, and Stephen Ross and Anthony Bossis, from New York University Grossman School of Medicine, discuss the role of psychedelic compounds like LSD, psilocybin, ayahuasca, and peyote in religious ceremonies. While uses of these substances vary among cultures and religions, the researchers note that they can induce experiences that share similarities to “non-pharmacologically triggered” experiences often described as “religious, spiritual, or mystical.”

“Mystical experiences are characterized by a range of subjective features including a sense of unity, “noetic” quality (e.g., an authoritative sense of truth), transcendence of time and space, a sense of awe or sacredness, intense positive mood, transiency that nevertheless feels timeless, presence in awareness of mutually exclusive states or concepts, and ineffability,” they explain.

The researchers note that such experiences are also sometimes observed in states of consciousness “associated with near-death experiences, meditation, prayer, fasting, breathwork, and music.” Although psychedelics continue to be used in some Indigenous religious contexts, the researchers note “they are generally not used within major world religions (e.g., Hinduism, Judaism, Buddhism, Christianity, Islam).”

Curious if these religious leaders would have similar experiences and how these experiences might affect their job performance, the team recruited volunteers from all four major religions. According to the results, the study participants experienced several impacts on their personal and professional lives, including “enduring increases in well-being and spirituality,” that lasted up to 16 months after taking magic mushrooms.

Keep reading

Nevada Lawmakers Pass Resolution Urging Congress To Reschedule Psychedelics And Expedite Research On Their Medical Benefits

The Nevada legislature has approved a joint resolution calling on Congress to reschedule certain psychedelics, streamline research and provide protections for people using the substances in compliance with state law.

After initially moving through the Senate and then the House with amendments, the Senate concurred to the other body’s changes and gave final approval to the proposal last Thursday.

SJR 10, from Sen. Rochelle Nguyen (D), has now been formally enacted and will be transmitted to President Donald Trump, Vice President JD Vance, House Speaker Mike Johnson (R) and all of the members of Nevada’s congressional delegation, as well as the heads of the Drug Enforcement Administration and National Institutes of Health.

The resolution cites research demonstrating the therapeutic potential of psychedelics in the treatment of serious mental health conditions and calls on the federal government to “reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA to a schedule that better reflects the therapeutic value, low potential for abuse and safety for use under medical supervision of those compounds.”

It also points out that there have been federal developments on the issue, including the Food and Drug Administration (FDA) designation of certain psychedelics as “breakthrough therapies” and research that’s being funded to explore the substances at the Department of Defense (DOD) and U.S. Department of Veterans Affairs (VA).

The measure urges Congress to increase funding for further research, establish a “streamlined process for approving and conducting research with psychedelic compounds,” and reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA under the Controlled Substances Act (CSA).

Further, it calls for the establishment of “legal protection against federal prosecution for individuals and entities complying with state law concerning the supervised adult use of psychedelic compounds and require states to enter research partnerships with the Attorney General under the Controlled Substances Act to study the public health outcomes of such state programs.”

The amendment adopted by the Assembly and now signed off on by the Senate “specifies that legal protections against federal prosecution shall be for individuals and entities who are compliant with state and local laws concerning the supervised adult use of psychedelic compounds,” Sen. James Ohrenschall (D) said on the floor.

Keep reading

“This Is Existential”: Billionaire Cancer Researcher Says Covid & Vaccine Likely Causing Surge In Aggressive Cancers

Dr. Patrick Soon-Shiong – a transplant surgeon-turned-biotech billionaire renowned for inventing the cancer drug Abraxane – has issued a startling warning in a new in-depth interview with Tucker Carlson.

Soon-Shiong, founder of ImmunityBio ($IBRX) and owner of the Los Angeles Times, claims that the COVID-19 pandemic, and the very vaccines developed to fight it, may be contributing to a global surge in “terrifyingly aggressive” cancers. In the nearly two-hour conversation, the Los Angeles Times owner leveraged his decades of clinical and scientific experience to outline why he suspects an unprecedented cancer epidemic is unfolding. This report examines Dr. Soon-Shiong’s background and assertions, the scientific responses for and against his claims, new data on post-COVID health trends, and the far-reaching implications if his alarming hypothesis proves true.

Dr. Soon-Shiong’s Claims

Soon-Shiong is a veteran surgeon and immunologist who has spent a career studying the human immune system’s fight against cancer. He pioneered novel immunotherapies and even worked on a T-cell based COVID vaccine booster during the pandemic. In the interview, he draws on this background to voice deep concern over rising cancer cases, especially among younger people – something he describes as a “non-infectious pandemic” of cancer. He tells Carlson that in 50 years of medical practice, it was extraordinarily rare to see cancers like pancreatic tumors in children or young adults, yet recently such cases are appearing. For instance, Soon-Shiong was alarmed by seeing a 13-year-old with metastatic pancreatic cancer, a scenario virtually unheard of in his prior experience. 

“I never saw pancreatic cancer in children… the greatest surprise to me was a 13-year-old with metastatic pancreatic cancer,” Soon-Shiong told Carlson, adding that he’s seen examples of very young patients (even children under 11 with colon cancer) and unusual surges in aggressive diseases like ovarian cancer in women in their 30s. These personal observations of more frequent, aggressive cancers in youth led him to probe what might have changed in recent years.

“We’re clearly seeing an increase in certain types of cancer, like pancreatic cancer, ovarian cancer… colon cancer… in younger people.”
— Dr. Patrick Soon-Shiong

According Soon-Shiong, the COVID era is the obvious change – and suggests that both the SARS-CoV-2 virus infection and the widespread vaccination campaigns could be key drivers behind this cancer spike. He emphasizes the massive scale of human exposure to the virus and its spike protein (via infection or vaccination).

“I don’t know how to say that without saying it. It scares the pants off me because I think what we may be, I don’ think it’s virus versus man now, this is existential. I think when I talk about the largest non-infectious pandemic that we’re afraid of, this is it.”

“Billions of people – literally billions – had the COVID virus. Over a billion got the spike protein vaccine,” said Carlson, adding “So that’s like, we’re talking like a huge percentage of the Earth’s population, unless I’m missing something.”

“Now you understand what keeps you awake at night and kept me awake at night for two years, two and a half years,” Soon-Shiong replied, suggesting that exposure to both is silently undermining the immune system’s natural defenses against cancer on a global scale.

Soon-Shiong frames COVID-era cancers as potentially virally triggered or exacerbated. In the interview, he described cases of “virally induced cancers” in clinics during the pandemic – patients whose cancers may have been kicked into overdrive by the cascade of inflammation and immune stress associated with COVID-19 (Dr. Patrick Soon-Shiong: You’re Being Lied to About Cancer, How It’s Caused, and How to Stop It). COVID infection causes a massive inflammatory response, and some cancers are known to exploit inflammation to grow.

TUCKER: “a lot people have pointed to both COVID, the virus, and to the mRNA COVID vaccines as potential causes. Do you think that they’re related?“

SOON-SHIONG: “The best way for me to answer that is to look at history. What we know about virally-induced cancers is well-established. We know that if you get hepatitis, you get liver cancer. Hepatitis is a virus infection. We know if you got human papillomavirus, HPV, you get cervical cancer.”

We know that certain viruses directly cause cancer (e.g. HPV, Epstein-Barr), so it’s not unprecedented for a virus to play a role in oncogenesis. While SARS-CoV-2 is not a known oncovirus, Soon-Shiong worries its indirect effects – chronic inflammation, immune exhaustion, or “suppressor cells” that emerge in the wake of infection/vaccination – could be accelerating tumor development. “The answer is to stop the inflammation…clear the virus from the body,” he argues, positing that until we eradicate lingering virus and restore immune balance, we may see mounting cancer cases.

Keep reading

Trump pledges to end the use of aborted baby tissues in federal investigation.

The Trump administration is about to take a monumental step in defending life and scientific ethics by banning the use of fetal tissues from abortions in research funded by the National Institutes of Health (NIH).

This decision, driven by Trump’s nominee to lead the NIH, Jay Bhattacharya, and backed by key figures such as Senator Josh Hawley and Health and Human Services Secretary Robert F. Kennedy Jr., marks a milestone in the pro-life movement and the search for ethical alternatives in science.

During a hearing before the Senate Committee on Health, Education, Labor, and Pensions, Trump’s NIH nominee, Jay Bhattacharya, explicitly promised to ban the use of fetal tissues from abortions in research funded by the institution.

When Senator Josh Hawley asked him if he supported Kennedy’s attempt to reinstate a policy from Trump’s first administration that severely restricted such investigation, Bhattacharya responded affirmatively, emphasizing that viable ethical alternatives exist.

@DrJBhattacharya promised that NO aborted fetal tissue will be used in NIH-funded research.

Keep reading

First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized anxiety disorder (GAD).

Drugmaker MindMed says that the trial, dubbed Voyage, is eventually expected to enroll about 200 people in the U.S. and will compare the effects of its proprietary LSD product to a placebo. A second Phase 3 trial, called Panorama, will also be conducted in both the U.S. and Europe and is expected to kick off in the first half of next year.

“Today marks a pivotal moment in our journey towards advancing a novel treatment option for the 20 million people in the U.S. living with GAD,” MindMed’s chief medical officer, Daniel R. Karlin, said in a statement released on Monday. “Building on our scientifically rigorous Phase 2b study, which demonstrated efficacy that far exceeds today’s standard of care and a favorable tolerability profile, our Phase 3 studies are designed to adhere to the highest clinical and ethical standards and are in alignment with guidance from the U.S. Food and Drug Administration.”

In March of this year, the Food and Drug Administration (FDA) granted MindMed’s LSD product “breakthrough therapy” status as a treatment for GAD. That followed a Phase 2 trial showing that a single oral dose of LSD led to “clinically and statistically significant” reductions in anxiety scores 12 weeks after administration, with 65 percent of participants showing a clinical response and 48 percent in clinical remission following the treatment.

Breakthrough drug status is meant to recognize the therapeutic promise of an emerging substance or therapy as well as speed the research and development of treatments that fill an unmet need. MDMA and psilocybin have also previously been awarded the designation.

The new research will use dissolvable oral tablets of the drug, MM120 ODT, or lysergide D-tartrate, which MindMed describes as a “proprietary and pharmaceutically optimized form of LSD.”

The first Phase 3 study, Voyage, will last a year and consist of two parts: a 12-week randomized, double-blind, placebo-controlled study to see how LSD affects anxiety symptoms. That will be followed by a 40-week extension period, during which participants can access open-label treatment with the drug based on the severity of their anxiety symptoms.

LSD has a noticeable subjective effect on sensation and cognition, which means it’s likely participants will know whether they received the psychedelic or a non-psychoactive placebo.

Keep reading

DEA Calls For Increased DMT Production In 2025 To Support Development Of FDA-Approved Psychedelic Drug

The Drug Enforcement Administration (DEA) is increasing the 2025 quota for the legal production of DMT in the U.S., saying it agrees with requests for the adjustment to “support legitimate research and scientific efforts” to develop a Food and Drug Administration- (FDA) approved drug based on the psychedelic.

In a notice set to be published in the Federal Register on Tuesday, DEA cited “additional quota applications and comments from DEA-registered manufacturers,” justifying the increase for the psychedelic compound.

DEA released initial quotas for the production of Schedule I and Schedule II controlled substances for research purposes in September. At the time, it called for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA.

But following a public comment period, it raised the production goal for DMT from 11,000 grams to 20,000 grams.

It’s not clear how close researchers are to developing a DMT-based drug, but several companies have indicated their intent to bring the psychedelic to market, pending regulatory approval.

Keep reading

A Psychedelic Ban Would Disrupt Important Research

You have probably never heard of 2,5-dimethoxy-4-iodoamphetamine (DOI), much less worried about its possible abuse. Yet the Drug Enforcement Administration (DEA) wants to ban this synthetic psychedelic, a promising research chemical used in more than 900 published studies, by placing it in Schedule I of the Controlled Substances Act. Students for Sensible Drug Policy (SSDP), which defeated a previous DEA attempt to ban DOI in 2022, is determined to stop the agency’s interference with science again.

A DEA administrative law judge has scheduled a 10-day hearing on the proposed ban, beginning on November 12. SSDP, which filed a prehearing statement on behalf of more than 20 scientists, argues that placing DOI in Schedule I would impose “onerous financial and bureaucratic obstacles on researchers.” SSDP also opposes the scheduling of another psychedelic, 2,5-dimethoxy-4-chloroamphetamine (DOC), under the same proposed rule, which the DEA published last December.

“DOI and DOC are important research chemicals with basically no evidence of abuse,” says SSDP alum and legal counsel Brett Phelps. Phelps is working with Denver attorney Robert Rush, who represents 
University of California, Berkeley, neuroscientist Raul Ramos.

“The DEA’s attempt to classify DOI, a compound of great significance to both psychedelic and fundamental serotonin research, as a Schedule I substance exemplifies an administrative agency overstepping its bounds,” Rush says. “The government admits DOI is not being diverted for use outside of scientific research yet insists on placing this substance in such a restricted class that it will disrupt virtually all current research.”

SSDP describes the two compounds as “essential research chemicals in pre-clinical psychiatry and neurobiology,” noting that their unscheduled status has made them accessible as tools for studying serotonin receptors. It says DOI, in particular, has been “a cornerstone in neuroscience research” due to its selectivity for the 5-HT2A serotonin receptor, crucial for understanding the therapeutic effects of psychedelics. Scientists have used DOI to “map the localization of an important serotonin receptor in the brain critical in learning, memory, and psychiatric disease,” SSDP notes, and DOI studies “have shown encouraging results in managing pain and reducing opioid cravings.”

The DEA argues that DOI and DOC “have a high potential for abuse.” While the two compounds “are available for purchase from legitimate chemical synthesis companies,” the DEA concedes, “there is no evidence of diversion from these companies.” But it notes that both drugs “have been encountered by law enforcement in the United States,” indicating their “availability for abuse.” Because “DOI and DOC are not found in FDA-approved drug products,” the DEA says, people who use them must be doing so “on their own initiative, rather than based on medical advice.”

Keep reading

DEA Calls To Increase Production of Psychedelics For Clinical Research

This week, the Drug Enforcement Administration (DEA) proposed increases to the production quotas of psilocybin, psilocin, and ibogaine for use by researchers investigating therapies with psychedelic compounds. The DEA oversees the regulated synthesis and cultivation of restricted psychoactive materials for scientific investigations.

A revised production agenda for 2024 calls for psilocybin and psilocin production to be increased by 50% – from 20,000 to 30,000 grams for psilocybin, and 24,000 to 36,000 grams for psilocin. These are the gram amounts planned for 2025 as well.

The DEA’s plans for 2025, posted as a notice in the Federal Register, includes the increased manufacturing of ibogaine from 150 to 210 grams. There is no change to the manufacturing level of other psychedelics such as MDMA or 5-MeO-DMT.

“This opens the door to more research, more clinical trials, and a better understanding of how we can apply emerging therapies,” says Representative Morgan Luttrell (R-TX). Luttrell is a former Navy SEAL whose therapeutic experiences with ibogaine and 5-MeO-DMT inform his advocacy for the government to fund psychedelic research, including allocations made in the fiscal 2024 National Defense Authorization Act. 

Expanding Research

The Controlled Substances Act, signed into law in 1970 by Richard Nixon, created five schedules under which to list drugs and allowed governmental regulation of how much of each drug could be produced for any purpose. Many psychedelics were placed under Schedule 1, the most limited schedule.

Researchers studying psychedelics in subsequent years faced scarce supplies of these substances, but their availability in recent years has grown significantly. In 2020 the DEA planned the production of just 30 grams of psilocybin; by 2024, the DEA increased the production to 20,000 grams.

The re-emergence of psychedelics as medicines is supported by expanding interest by researchers to study these compounds for their potential for effective treatments for mental health issues including depression, PTSD, and substance use disorder. Substances like psilocybin, psilocin and ibogaine are still listed in Schedule 1, which declares that they have no currently-accepted medical use. Researchers are investigating new treatments for mental health disorders through a variety of proposed mechanisms – such as by re-opening critical periods of learning or by collapsing default mode network activity in the brain. 

Despite promising areas of research to find new mental health treatments, DEA scheduling has been a major impediment into research on psychedelics, says Dalibor Sames, a professor of chemistry at Columbia University who studies iboga alkaloids. “While we have the DEA license, it is highly inefficient and cumbersome to share scheduled substances with collaborators,” he says. “Research in these days is highly collaborative and thus sharing compounds and other research items is an essential part of doing science and drug discovery today.”

By increasing their production quotas, DEA appears to be signaling their intent to support psychedelic research, stating in the revised 2024 notice: “These proposed increases demonstrate DEA’s support for research with schedule I controlled substances,” writes the agency. “The proposed increases reflect research and development needs as part of the process for seeking the FDA approval of new drug products.”

For researchers like Sames, who uses small amounts of iboga alkaloids in the study of psychedelic chemistry, the new quota has no immediate impact. But the increased availability of these three drugs could influence their availability for use in clinical trials with human subjects. 

Keep reading